SOLICITATION NOTICE
A -- Measles-Mumps-Rubella (MMR) vaccine study - PWS
- Notice Date
- 9/3/2013
- Notice Type
- Presolicitation
- NAICS
- 541380
— Testing Laboratories
- Contracting Office
- Department of Health and Human Services, Centers for Disease Control and Prevention, Procurement and Grants Office (Atlanta), 2920 Brandywine Road, Room 3000, Atlanta, Georgia, 30341-4146
- ZIP Code
- 30341-4146
- Solicitation Number
- 2013-52502
- Archive Date
- 10/3/2013
- Point of Contact
- Maria S Shamburger,
- E-Mail Address
-
HEG9@cdc.gov
(HEG9@cdc.gov)
- Small Business Set-Aside
- N/A
- Description
- Performance Work Statement The Centers for Disease Control and Prevention, NCIRD/DVD, 1600 Clifton Rd. NE, Atlanta, GA, 30333, hereby announces its intent to issue a sole source contract in accordance with FAR 6.302-1 to Marshfield Clinic Research Foundation, 1000 N Oak Ave., Marshfield, WI 54449 to perform a study on an existing cohort of patients receiving a third dose of MMR vaccine at 3, 6 and 10 year intervals. The results of this study will be used to determine the persistence of levels of measles, mumps and rubella antibodies among participants of the original "MMR3 Study". The statutory authority permitting other than full and open competition is 41 U.S.C. 253(c)(1) as cited in FAR 6.302-1, "Only one responsible source and no other supplies or services will satisfy agency requirements." Marshfield Clinic has access to a cohort of 665 subjects who received their third dose of MMR vaccine as part of the "MMR3 Study" that is well characterized; their sera results are available from immediately prior to the third MMR vaccine dose, as well as one month and one year following the administration of the third dose. In addition, for 119 (18%) of the 665 clients, we have serological data at multiple time points over a 12 year period following their second dose of MMR vaccine. The serologies at these time points will allow us to make comparisons to detect whether waning immunity is an issue after both the second and third MMR dose. We will also be able to compare whether persons who responded well after a second dose of MMR vaccine also responded well after a third dose. These subjects are clients of the Marshfield Clinic. Thus, the Marshfield Clinic Research Foundation is the only agency that has access to these individuals. We have baseline serological data on these subjects prior to their third MMR vaccine dose, as well as at 1 month and 1 year following their 3rd dose. No other population would be able to give us this information since a 3rd dose of MMR vaccine is not routinely administered. The 665 subjects is the only cohort that has been utilized in this study previously. It is necessary to continue to use this cohort to ensure the study results can be produced. It is not useful obtaining sera on another cohort if we do not have pre-vaccination sera on them, and if we do not have sera at other time points. The point of the study is to assess the change in titer levels in these individuals over time so that we can see if waning immunity is occurring or if the titer levels remain stable over time after a 3rd MMR dose. Responsible sources that believe they possess the expertise and capabilities identified above are encouraged to submit to the Contracting Officer within 15 days from the posting date of this notice, their written capabilities statement which shall be considered by the agency. Please forward the capability statement information to Maria Shamburger, Contracting Specialist, Reference 2013-52502, Centers for Disease Control, Procurement and Grants Office, ATTN: Maria Shamburger, MS: K14, 2920 Brandywine Road, Atlanta, GA 30341. All vendors must be registered in the System for Award Management (SAM) prior to an award of a federal contract. The website is: www.sam.gov. The Government will review any/all capabilities statements submitted and determine if other qualified sources do exist that could provide this requirement. Information received in response to this announcement will be used solely for the purpose of determining whether to conduct a competitive procurement. If no affirmative responses are received within 15 days, negotiations will be conducted with the Marshfield Clinic Research Foundation as the only source and a contract will be issued without any additional notices being posted.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/CDCP/PGOA/2013-52502/listing.html)
- Place of Performance
- Address: 1000 N Oak Ave., Marshfield, Wisconsin, 54449, United States
- Zip Code: 54449
- Zip Code: 54449
- Record
- SN03171672-W 20130905/130903235412-fa4c8cfa12a5cd250c50a8a1ee105d63 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |